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RISK-BENEFIT ANALYSIS OF SOLID TUMOR VS. BLOOD/METASTATIC 
CANCER TREATMENT WITH REOVIRUS 
 
YOUSIF KETTOOLA 
 
 
 
ABSTRACT 
 In the past several years, cancer treatments using FDA approved immune 
checkpoint inhibitors have become more popular than common 
chemotherapeutic agents.  However, the costs, risks, and benefits associated 
with these treatments are still being assessed.  Currently, new therapies are 
being tested that utilize oncolytic viruses to treat solid tumor and metastatic 
cancers.  Reovirus is a non-enveloped virus with a double capsid structure and a 
genome consisting of 10 segments of double-stranded RNA encoding eleven 
proteins, which has been shown to have effective oncolytic activity. There are 
various different strains of reoviruses that can produce cytopathic effects in 
mammalian host cells. Moreover, several studies have shown that reovirus can 
be administered in multiple ways and that administration may depend on the 
cancer type. This investigation examined the type 3 dearing strain of reovirus and 
whether different types of tumors would benefit from having a specific 
administration appropriate to their type such as intratumoral injections for solid 
tumors and intravenous administration for blood/metastatic cancers. Various 
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clinical trials were assessed in which reovirus was administered intratumorally, 
intravenously at a maximum dose of 3x1010 TCID50, and in combinations with 
other cancer therapeutics. Reovirus was shown to be safe and well-tolerated 
across a variety of administrations and cancer morphologies. Moreover, along 
with its cytopathic effects, reovirus was shown to have potent immune system 
stimulating effects. Overall, intratumoral administration was preferred effective for 
solid tumor cancers while intravenous administration was preferred for blood and 
metastatic cancers. 	
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INTRODUCTION 
Cancer is the second leading cause of death in the United States after 
heart disease. Patients diagnosed with cancer such as local or metastatic 
melanoma have five-year survival rates of 98% and 17% respectively (Kohn et al. 
2017).  In the past several years, cancer treatments using US Food and Drug 
Administration (FDA) approved immune checkpoint inhibitors have become more 
popular as treatment options when compared to common chemotherapeutic 
agents (Kohn et al. 2017). However, the costs, risks, and benefits associated 
with these treatments are still being assessed. As seen in Table 1, although 
immune checkpoint inhibitors have displayed great efficacy in the treatment of 
cancers when other therapies have been unsuccessful, they have also been 
shown to not be effective at times or produce adverse events, such as the 
development of autoimmune disease, which increase the risk of using these 
types of therapies (Kohn et al. 2017).   
Currently, new therapies are being tested that utilize oncolytic viruses to 
treat solid tumor and metastatic cancers. Oncolytic viruses specifically infect and 
kill cancer cells while leaving normal cells largely unharmed (Su, Jia, and Chen 
2016).  Oncolytic viruses can be injected into a tumor directly or inoculated into a 
cancer patient. Once the virus encounters and infects a cancer cell, it will 
replicate in that cell resulting in the release of progeny virions that can go on to 
infect other cancer cells once the cell is lysed (Su, Jia, and Chen 2016).  Some 
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studies have shown that the anti-tumor efficacy of oncolytic viruses is also due to 
their ability to act as potent inducers of host immunity (Samson et al. 2016).  
 
Table 1. Adverse Events Produced by Cancer Therapies. Various adverse 
events, both immune-derived and nonimmune-derived, occur in subjects treated 
with immune checkpoint inhibitors. The immune checkpoint inhibitors include 
pembrolizumab, ipilimumab, and nivolumab. (Kohn et al., 2017)
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Reovirus is a non-enveloped virus with a double capsid structure and a 
genome consisting of 10 segments of double-stranded RNA encoding eleven 
proteins, that has been shown to have effective oncolytic activity (Kolb et al. 
2015).  Reovirus strains infecting humans are ubiquitous and most likely 
transmitted via the fecal-oral route and respiratory secretions. The prevalence of 
antibodies against reovirus in more than half of normal, healthy adults indicate 
that a majority of adults have had prior infections with reovirus, mostly likely as 
children (Kolb et al. 2015). Reovirus infections may be asymptomatic or 
associated with symptoms similar to the common cold, or diarrhea, usually in 
children with their first infection (Gasparinho et al. 2017). Reovirus infections in 
humans have not been definitively shown to cause serious illness, and were 
named based on the lack of association with specific disease, respiratory enteric 
orphan virus. However, some studies suggest it may be associated with 
extrahepatobiliary atresia (EHBA) in infants (Richardson, Bishop, and Smith 
1994). In studies of reovirus pathogenesis in mouse models, specific strains of 
reovirus cause lethal encephalitis, hydrocephalus, or biliary atresia, but only in 
infected neonatal mice, not when adult mice are inoculated with virus (Derrien 
and Fields 1999) (Wilson, Morrison, and Fields 1994).   
In natural infections with reovirus, the virus most commonly enters the GI 
tract and undergoes limited proteolysis of the outer capsid, generating an 
infectious subviral particle (ISVP). Only ISVP’s are capable of productively 
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infecting susceptible cells. ISVP’s bind to receptors found on many cell types and 
enter cells via receptor-mediated endocytosis. Further proteolysis in endosomes 
results in disassembly of the outer capsid (Sakurai et al., 2017). However, unlike 
most other viruses, reovirus virions are not completely disassembled and viral 
transcription occurs within the partially uncoated virus particles in the cytoplasm. 
The virion contains all the enzymes required for transcribing viral mRNAs which 
are released through openings in the vertices of the capsid. Viral mRNAs are 
translated in the cytoplasm and capsid proteins assemble into icosahedral viral 
structures. Some of the viral mRNAs, one each of the 10 different genomic 
strands, are packaged into these capsids, along with newly-synthesized viral 
RNA polymerase. Replication of the viral genome is completed when the viral 
RNA polymerase uses each of the ten mRNAs as a template to transcribe the 
complimentary negative strand, generating the 10 double-stranded genome 
segments, within the capsids. Progeny virions accumulate in the cell cytoplasm 
until the cell lyses and they are released. Due to errors that occur during viral 
replication, many of the progeny virions released are defective (replication 
incompetent), often due to packaging errors resulting in virions that lack viral 
RNA, contain less than the ten genome segments or lack one or more of the ten 
genome segments (Martinez-Costas, Varela, and Benavente 1995) (Ogden, 
Ramanathan, and Patton 2011).  
Reovirus has been shown to effectively kill tumor cells with an activated 
Ras pathway.  Studies have shown this may be due to the inhibition of double-
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stranded RNA-activated protein kinase (PKR) by activated Ras (Strong et al. 
1998). As Figure 1 shows, when Ras is inactive, PKR is autophosphorylated in 
the presence of viral RNA and inhibits viral protein synthesis and replication. 
However, Ras activation is believed to induce downstream signals that inhibit 
PKR autophosphorylation and allow viral protein synthesis and replication to 
occur (Strong et al. 1998). One study provides evidence that MEK, a protein 
kinase downstream of Ras signaling pathway, is responsible for the inhibition of 
PKR phosphorylation (Veerapong et al. 2007).  Although tumor cells with an 
activated Ras pathway are efficiently killed by reovirus, Sakurai and colleagues 
concluded that Ras-activation status does not seem to be correlated with the 
ability of reovirus to kill these cells (Sakurai et al. 2017). It seems that cathepsins 
B and L, cysteine proteases found in the endolysosomes, play a vital role in 
active infection and tumor-killing ability of reovirus (Sakurai et al. 2017). These 
cathepsins are responsible for the proteolytic disassembly of reovirus. Thus, 
tumors with high activities of cathepsins B and L are efficiently lysed by reovirus 
while tumors with low activity are usually resistant to reovirus oncolysis, likely 
due to inefficient endo/lysosomal escape (Sakurai et al. 2017).   
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Figure 1. Ras Downstream Signaling Effects on PKR. Ras activation leads to 
downstream signaling that prevents PKR phosphorylation and allows for 
translation of viral genes. In the absence of Ras activation PKR is 
phosphorylated and prevents the initiation of viral gene translation. (Villalona-
Calero et al. 2016) 
 
 
 
Several studies have shown that reovirus can be administered in multiple 
ways and that its efficacy in killing tumor cells may be improved by varying the 
mode of administration depending on the cancer type.  In their study of 
hepatocellular carcinoma, a solid tumor cancer, Samson et al. used 
		
 7	
subcutaneous injections to deliver reovirus into the host and induce its antitumor 
effect (2016). Moreover, in their investigation of reovirus against lung carcinoma 
and melanoma, Campion and colleagues used intratumoral injections of reovirus 
to treat mice in vivo (Campion, Soden, and Forde 2016). Both studies resulted in 
prolongation of survival and delayed tumor growth along with upregulation of 
cytokines following treatment. When examining blood cancers, such as leukemia, 
Parrish and colleagues described how treatment of solid tumor cancers with 
systemic delivery of oncolytic viruses, such as reovirus, might be problematic due 
to decreased viral load at the tumor locale. However, for hematological 
malignancies, systemic delivery is ideal (Parrish et al. 2015).  
Finally, although cancer therapy with reovirus has many potential benefits, 
there may also be some adverse outcomes. One study suggests that reovirus 
may lead to stimulation of helper T cells against dietary gluten leading to celiac 
disease (Bouziat et al. 2017).  Another worry is that reovirus may not be as 
effective in patients with preexisting neutralizing anti-reoviral antibodies (NARA) 
due to previous reovirus infections (Harrington et al. 2010). In this analysis, the 
risks and benefits of using reovirus as a therapy for both solid tumor cancers and 
blood/metastatic cancers will be assessed. This investigation hypothesizes that 
the benefits of utilizing reovirus as an effective therapy for cancers such as 
melanoma, leukemia, breast, soft tissue sarcoma, etc. will outweigh the toxicities 
that might be incurred in patients after its administration. 
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SPECIFIC AIMS 
1. Review the current knowledge of the mechanisms of reovirus infection and 
cell killing, including by apoptosis.  
 
2. Evaluate the findings from current studies regarding the efficacy and 
benefits of reovirus treatments in both solid tumor cancers and 
blood/metastatic cancers. 
 
3. Compare the effects of different modes of administration of reovirus on the 
efficacy of treatment for different types of cancer, e.g. solid tumors vs. 
blood cancers.  
 
4. Investigate of the risks involved when using reovirus to treat different solid 
tumor and blood/metastatic cancers and how the administration influences 
those risks.  
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REOVIRUS AND REOLYSIN® 
 Reovirus is a member of the Orthoreovirus genus of the Reoviridae family, 
a large family that includes viruses that infect humans, animals and insects. The 
best-known human pathogen in this family is rotavirus, which was a widespread 
cause of infantile diarrhea before vaccines for it were developed. Reovirus 
conatains a double stranded RNA genome made up of 10 segments labeled by 
their size: large (L1, L2, and L3), medium (M1, M2, and M3), and small (S1, S2, 
S3, and S4) (Chakrabarty et al. 2014).  There are various different strains of 
reoviruses that can produce cytopathic effects in a variety of mammalian host 
cells (Tyler et al. 1995). Of these strains, the type Lang (T1L) and type 3 Dearing 
(T3D) have been shown to induce apoptosis in cultured cells, with T3D inducing 
apoptosis to a greater extent than T1L (Tyler et al. 1995).  
Reolysin®, also known as pelareorep, is a new investigational drug that is 
composed of live, replication-competent reovirus T3D strain in its purified form 
(Chakrabarty et al. 2014). In their study on the homogeneity and stability of the 
reovirus genome, Chakrabarty and colleagues found that T3D reovirus displays 
high genetic and genomic stability after several cycles of replication in cell 
cultures (Chakrabarty et al. 2014). Their investigation found 27 modifications to 
the genome when compared to public databases such as GenBank and 
concluded that these modifications gave reovirus some growth advantages.  
After examining the genomic stability of Reolysin®, Chakrabarty and colleagues 
also conducted a phylogenetic analysis using the L1 segment of Reolysin® virus 
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and other reoviruses, including those from different genera and host specificities 
(Figure 2). As expected, Reolysin® was most similar to T3D and T1L reovirus 
strains and also showed similarity to other mammalian reoviruses. 
Figure 2. Phylogenetic Tree of Members from Orthoreovirus genus. This 
tree displays the evolutionary relationship between various different 
orthoreoviruses based on the L1 segment of their genome. There are four main 
clusters indicated as human and porcine, primates, bat-borne, and avian. Branch 
support values are shown as a percentage and the scale-bar represents 0.5 
substitutions per site. (Chakrabarty et al., 2014) 
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MECHANISMS OF INFECTION 
 
 Previous research has demonstrated that reoviruses can preferentially 
infect, replicate, and induce cell death in transformed cells, particularly those with 
activating Ras mutations (Carew et al. 2013). However, recent studies have 
found that Ras activation status does not influence cell sensitivity to reovirus 
infection and killing and therefore should not be used as a biomarker when 
selecting patients for clinical trials involving reovirus (Twigger et al. 2012).   
 The S1 segment of the reovirus genome encodes for the viral attachment 
protein, 𝜎1, which determines reovirus tropism.  𝜎1 protein can bind two types of 
cellular receptors using independent receptor-binding domains (Barton et al. 
2001).  In their search for a cellular receptor for reovirus 𝜎1 protein, Barton and 
colleagues used an expression-cloning approach to identify junction adhesion 
molecule (JAM) as a reovirus receptor (Barton et al. 2001). T3D reovirus was 
shown to be dependent on JAM– 𝜎1 interactions to establish infection in host 
cells (Barton et al. 2001). 
Similarly, in their investigation of the mechanisms of the anti-neoplastic 
effects of reovirus in multiple myeloma patients, Kelly and colleagues also 
demonstrated that cellular expression of junctional adhesion molecule-A (JAM-A) 
can determine susceptibility to reovirus infection (Kelly et al., 2015).  JAM-A is an 
immunoglobulin superfamily protein expressed on various blood cells such as 
circulating neutrophils, monocytes, and lymphocytes (Kelly et al., 2015).  JAM-A 
has many functions including the regulation of tight junctions between cells and 
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research on its use as a prognostic indicator of cancer progression is currently 
emerging (Kelly et al. 2015).  
Kelly and colleagues observed how transformed cell lines with low JAM-A 
expression showed low levels of reovirus cell entry and replication while others 
with high JAM-A expression showed greater susceptibility to reovirus infection 
(Kelly et al. 2015).  Moreover, after treatment of multiple myeloma with the 
proteasome inhibitor bortezomib (BZ), relapsed cells showed increased JAM-A 
expression leading to a greater susceptibility of these cells to reovirus infection 
(Kelly et al. 2015).  This study highlights the potential of reovirus as a treatment 
when cancer cells have become resistant to a previous treatment.  
 
MECHANISMS OF APOPTOSIS 
While JAM- 𝜎1 interactions may help reovirus enter the host cell, 
investigations still need to be done to determine how reovirus exerts its effects 
once inside. Previous investigations have shown that cell and tissue injury 
induced by reovirus is associated with apoptosis (Oberhaus et al. 1997). Carew 
and colleagues investigated the effects of reovirus on pancreatic cancers since 
mutated Ras is prevalent in pancreatic cancers and reoviruses have been shown 
to be selective to cells with Ras activating mutations. In their investigation, Carew 
and colleagues demonstrated that reovirus infection led to apoptosis mediated by 
endoplasmic reticular (ER) stress including ER swelling, increased calcium levels 
in the cytosol, elevated expression of ER stress genes, and processing of 
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caspase-4 (Carew et al. 2013). Since previous studies had shown that 
processing of caspase-4 was characteristic of ER stress-mediated apoptosis, 
they also found that knocking out caspase-4 led to a significant reduction in 
reovirus-induced apoptosis (Carew et al. 2013).  
Interestingly, Carew and colleagues also conducted experiments in which 
they treated pancreatic cancer cells with both BZ and Reolysin® in vitro and in 
vivo in mice and found that BZ augmented the effects of Reolysin® (Carew et al. 
2013).  Similarly, in their investigation of Reolysin use in multiple myeloma, Kelly 
and colleagues also found that reovirus infection and replication in multiple 
myeloma cells led to ER-stress mediated apoptosis of the infected cells (Kelly et 
al. 2012). Cotreatment with Reolysin® and BZ in multiple myeloma also showed 
elevated levels of ER stress due to the increased accumulation of viral and 
ubiquitinated proteins (Kelly et al., 2012).   
 
LOCAL/INTRATUMORAL REOVIRUS TREATMENT – SOLID TUMORS 
In their phase I trial treating patients with advanced solid tumors, Morris 
and colleagues used a dose-escalation design with percutaneous, intralesional 
administration of Reolysin® (Morris et al., 2013). Nineteen patients with different 
solid tumor cancers, including soft tissue sarcoma, head and neck cancer, and 
breast cancer were enrolled in the study as seen in Table 2 (Morris et al., 2013). 
Intralesional administration was conducted in an outpatient setting under sterile 
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conditions and patients were monitored for two hours following the procedure 
(Morris et al. 2013).  
 
 
Table 2. Patient Demographics and Tumor Diagnoses in a Study of 
Intralesional Reovirus Administration. The characteristics of the patients 
enrolled in this study are shown. This table also displays the previous therapies 
that the patients may have had prior to enrollment. (Morris et al, 2013) 
 
Patient characteristics No. patients 
Total No. 19 
Age (years) 
 Median 51 
 Range 27–75 
Male/Female 9/10 
Primary tumor site 
 Soft tissue sarcoma 5 
 Head and neck 4 
 Melanoma 4 
 Breast 3 
 Other 3 
Eastern Cooperative Oncology Group Performance Status 
 0 12 
 1 7 
Prior surgery 16 
Prior radiotherapy 10 
Prior chemotherapy 15 
 Median Regimens (range) 2 (0–5) 
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In order to evaluate tumor responses to Reolysin® treatment, patients were 
monitored for 14 weeks, with responses being evaluated once a week for the first 
6 weeks and then at weeks 10 and 14 afterwards. Tumors were manually 
measured using calipers and clinical responses were determined by Response 
Evaluation Criteria in Solid Tumors (RECIST) for progressive disease (PD), 
stable disease (SD), partial response (PR) and complete response (CR) 
(Therasse et al. 2000). The best target tumor response at/after 6 weeks follow-up 
was CR in one (5.3%), PR in two (10.5%), SD in four (21.1%) and PD in ten 
(52.6%) patients, indicating a statistically significant treatment efficacy for the 
local tumors (Morris et al. 2013). However, no significant anti-tumor activity was 
found for tumor lesions in sites remote from the viral administration site. This is 
believed to be due to the NARA response that prevents the spread of virus.  
One major finding in the Morris study was that percutaneous intralesional 
administration of Reolysin® to oncology patients with a variety of cancers and 
was well-tolerated and safe. The chief toxicities observed were mild, including 
nausea, vomiting, diarrhea, injection site erythema, and fever/chills (Morris et al. 
2013). Moreover no dose limiting toxicity (DLT) was found, even at the highest 
dose used of 1x1010 plaque forming units (PFU), and thus the maximum tolerated 
dose (MTD) could not be defined (Morris et al. 2013). 
In their phase I clinical trial of genetically unmodified, T3D reovirus and its 
use in malignant gliomas, Forsyth and colleagues also used intratumoral 
injections to help define a DLT/MTD and examine tumor responses to reovirus. 
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Twelve patients with a median age of 53.5 years and history of recurrent 
malignant glioma were enrolled in the study. As shown in Table 3, the patients 
had varying brain tumor histologies and various prior therapies including 
radiotherapy and chemotherapy (Forsyth et al. 2008).  
 
 
Table 3. Demographics of Patients with Malignant Glioma in an Intratumoral 
Injection Trial . The characteristics of the patients enrolled in this study are 
shown. This table also displays the previous therapies that the patients may have 
had prior to enrollment and the distribution of patients among the doses. (Forsyth 
et al., 2008) 
 
 # Patients  %  
Gender   
 Male 7 58 
 Female 5 42 
Performance status (KPS)   
 60 3 25 
 70 2 17 
 80 2 17 
 90 5 42 
Histology at first diagnosis of brain tumor   
 Oligoastrocytoma grade II 1 8 
 Anaplastic oligoastrocytoma 1 8 
 Anaplastic astrocytoma 3 25 
 Glioblastoma multiforme 7 58 
Histology of recurrence prior to Reovirus 
administration   
 Anaplastic astrocytoma 2 17 
 Anaplastic oligoastrocytoma 1 8 
 Glioblastoma multiforme 9 75 
Prior therapy   
 Radiotherapy (60 Gy) 2 100 
 Adjuvant chemotherapy 10 83 
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Other medications at baseline   
 Corticosteroids 6 50 
 Anticonvulsants 12 100 
Dose (TCID50)   
 107 3 25 
 108 6 50 
 109 3 25 
Surgery at Recurrence post administration   
 Resection 6 50 
 None 6 50 
 
  
Tumor responses were evaluated using standard criteria with one patient 
having SD, ten patients having PD, and one patient not evaluable for response 
due to a small hemorrhage leading to surgery (Forsyth et al., 2008). Moreover 
several patients had longer-than-expected survivals and one remains a long-term 
survivor, but that may have been due to selection criteria for the study rather than 
reovirus treatment (Forsyth et al., 2008).   
 Similar to the previous study by Morris, the major finding in this research 
study is that administration of reovirus intracerebrally, directly into brain tumors of 
patients with malignant glioma, was safe and well-tolerated at the doses used 
(Forsyth et al., 2008). The maximum dose used was 1x109 tissue culture 
infectious dose 50 (TCID50) and the most common adverse event seen was a 
deterioration of motor strength that was due to tumor progression rather than 
treatment with reovirus (Forsyth et al., 2008).  
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 In another phase I clinical trial examining reovirus and its use in malignant 
gliomas, Kicielinski and colleagues used a different technique to administer 
Reolysin® to patients. This investigation used an appropriate placement of 
catheters to allow for direct infusion of reovirus into the tumor (Kicielinski et al., 
2014). This delivery method is called convection-enhanced delivery (CED) and 
relies on sustained, low-pressure infusion with a catheter to allow for enhanced 
delivery to the site of interest while limiting systemic side effects and enhancing 
efficacy (Kicielinski et al., 2014). 
 Eighteen patients were enrolled in this trial, but only fifteen were treated. 
Three patients displayed pathologies with grade 3 tumors (anaplastic 
astrocytomas) and the remaining patients displayed grade 4 tumors 
(glioblastoma multiforme) (Kicielinski et al. 2014). This investigation used a does-
escalation method with doses ranging from 1x108 to 1x1010 TCID50.  
 Tumor responses to the treatment were analyzed using standard criteria 
and at the best response during the study period 10 patients had SD, 1 had PR, 
and 4 had PD.  By the time of the study’s discontinuation, 2 patients had SD, 1 
had PR, and 12 had PD (Kicielinski et al. 2014). Although many of the SD 
patients eventually returned to PD, the study demonstrates that treatment with 
reovirus managed to help a few patients, showing its potential to combat 
malignant gliomas. Moreover, several of the patients that participated in the study 
experienced prolonged survival, which was likely due to the treatment with 
reovirus.  
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 The main goal of this experiment was to analyze the safety and tolerability 
of Reolysin® treatment. Even with a maximum dose of 1x1010 TCID50, no DLT 
was reached and so no MTD was discovered. The most common adverse events 
experienced were convulsions and seizures which occurred in 2 patients at the 
highest dose level, but were determined to be unrelated to reovirus and the 
infusion delivery method (Kicielinski et al., 2014). CED of reovirus was well 
tolerated by the patients, but further investigations into reovirus at the highest 
dose level should be done to confirm the safety of this protocol.   
In another phase I clinical trial, Harrington and colleagues combined 
radiotherapy with intratumoral reovirus treatment in patients with advanced solid 
tumor cancers. Twenty-three patients with advanced or metastatic solid tumors 
were treated in this study. These patients had varying tumor types including 
melanoma, head and neck cancer, lung cancer, pancreatic cancer, and 
colorectal cancer. The median age for patients was 58.6 with ages ranging from 
38-75 (Harrington et al., 2010). 
The study was conducted in two stages. In the first stage, radiotherapy 
was given as local tumor irradiation at a dose of 20 Gy in five consecutive daily 
fractions along with two intratumoral injections of Reolysin® at doses between 
1x108 to 1x1010 TCID50 (Harrington et al., 2010). In the second stage, patients 
received local tumor irradiation at a dose of 36 Gy in 12 fractions over 16 days 
with two, four, or six doses of T3D reovirus at doses of 1x1010 TCID50 (Harrington 
et al., 2010). A previous study showed in vitro and in vivo data that provided 
		
 20	
evidence for a synergistic effect between reovirus and radiotherapy that 
prompted this investigation (Twigger et al., 2008).  
 Overall, treatment was well-tolerated in all cohorts of the study. The most 
common toxicities observed included pyrexia, flu-like symptoms, vomiting, 
asymptomatic lymphopenia, and neutropenia (Harrington et al., 2010).  However, 
researchers determined that neither reovirus treatement nor radiotherapy were 
responsible for these toxicities. No DLT was reached in this study and thus no 
MTD was found. Like the previous studies, this investigation demonstrated that 
intratumoral injections of reovirus at a dose of 1x1010 TCID50 were well-tolerated 
and recommended for future studies. 
 Of the twenty-three patients treated, fourteen were evaluable for treatment 
response. From the patients in the first stage, 2 out of 7 had PR and the other 5 
had SD. From patients in the second stage, 5 out of 7 had PR and the other 2 
had SD (Harrington et al. 2010). However, it is not possible to draw conclusions 
on the influence that Reolysin® had on the tumor responses. Overall, this 
investigation demonstrated the possibility of combining reovirus with current 
cancer therapies such as radiation and further supports its safety.  
  
INTRAVENOUS REOVIRUS TREATMENT – SOLID TUMORS 
While intratumoral administration of T3D reovirus for solid tumor cancers 
has been shown several times to be safe and well-tolerated, researchers also 
began investigating the possibility of administering reovirus intravenously. In their 
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phase I clinical trial, Kolb and colleagues examined the effects of treating 
children with extra-cranial solid tumors with Reolysin®. For 5 consecutive days 
every 28 days reovirus was administered intravenously to patients in one of three 
dose levels including 3x108 TCID50/kg of weight, 5x108 TCID50/kg of weight, and 
5x108 TCID50/kg of weight + 50 mg/m2/day of oral cyclophosphamide for 21 
consecutive days every 28 days (Kolb et al., 2015).   
Twenty-nine patients were enrolled in the study but only twenty-four were 
evaluable. Patients had a median age of 12.5 years with ages ranging from 3 to 
20.2 years and were of different races as seen in Table 4. Moreover, patients 
displayed varying tumor types, including Wilms tumor, neuroblastoma, 
osteosarcoma, retinoblastoma, etc. (Kolb et al., 2015). Tumor response 
assessments were done with RECIST criteria. 
 
Table 4. Patient Demographics in a Study of Intravenous Administration of 
Reovirus. The characteristics of the patients enrolled in this study are shown. 
This table also displays the previous therapies that the patients may have had 
prior to enrollment. (Kolb et al., 2015) 
 
Characteristic Number (%) 
Age (years)  
Median 12.5 years 
Range 3.0–20.2 years 
Sex  
Male 19 (67.9) 
Female 9 (32.1) 
Race  
White 18 (64.3) 
Asian 2 (7.1) 
Native American 1 (3.6) 
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Characteristic Number (%) 
Pacific Islander 1(3.6) 
Black or African American 4 (14.3) 
Ethnicity 2 (7.1) 
Non-Hispanic 24 (85.7) 
Hispanic 4 (14.3) 
Diagnosis  
Alveolar rhabdomyosarcoma 2 (7.1) 
Chondroblastic osteosarcoma 1 (3.6) 
Clear cell sarcoma 1 (3.6) 
Desmoplastic small round cell tumor 1 (3.6) 
Embryonal rhabdomyosarcoma 3 (10.7) 
Ewing sarcoma 3 (10.7) 
Germ cell tumor 1 (3.6) 
Hemangiosarcoma/angiosarcoma 1 (3.6) 
Hepatoblastoma 2 (7.1) 
Neoplasm, malignant/Tumor, malignant, NOS 1 (3.6) 
Wilms tumor 3 (10.7) 
Neuroblastoma 2 (7.1) 
Osteosarcoma 3 (10.7) 
Retinoblastoma 1 (3.6) 
Synovial sarcoma 2 (7.1) 
Prior Therapy  
Chemotherapy Regimens  
Median 3 
Range 1–8 
Number of patients with prior radiation therapy 20 (71.4) 
 
  
Overall, the study concluded that reovirus can be administered safely to 
children and an MTD was not reached. Interestingly, a DLT was reported for one 
patient at a dose level of 3x108 TCID50/kg and the patient went into respiratory 
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failure and died. However, this adverse event was attributed to progressive 
disease and unlikely caused by the treatment. Another DLT was reported for one 
patient with synovial sarcoma at a dose level of 5x108 TCID50/kg. The patient 
experienced increasing shortness of breath and a deep venous thrombosis, 
which were attributed to Reolysin® treatment and progressive disease. Other 
common toxicities included abdominal pain, chills, diarrhea, fatigue, fever, and 
headaches (Kolb et al., 2015).  
 When looking at tumor responses, the study did not report any CR or PR. 
Three patients were reported to have SD at one point in the study. 
Cyclophosphamide is an immunosuppressive drug that the researchers hoped 
would increase intratumoral virus levels and tumor response. While tumor 
response may not have been affected much by the combined treatment (or 
reovirus alone), no DLTs for the combined therapy were reported and viral 
clearance was not impacted (Kolb et al., 2015). This suggests that this combined 
therapy was safe and could be used in future studies of Reolysin® in patients.  
   
INTRAVENOUS REOVIRUS TREATMENT – METASTATIC CANCERS 
In their investigation of intravenous administration of Reolysin® in patients 
with advanced solid tumors, Gollamudi and colleagues used six dose cohorts to 
evaluate the safety of systemic treatment of Reolysin®. Reolysin® was given as a 
one-hour intravenous infusion every 28 days with the lowest dose cohort being 
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1x108 TCID50 and the highest dose cohort being 3x1010 TCID50 (Gollamudi et al., 
2010). 
 Eighteen patients were enrolled in the study with a median age of 57 
years and ages ranging from 40-72 years. Patients had various cancers, 
including colon cancer, ovarian cancer, prostate cancer, and breast cancer. 
Since they were being treated with live virus, patients were asked to stay at 
home as much as possible in the first five days of treatment and wear masks for 
2 weeks when around others (Gollamudi et al., 2010).   
 The common toxicities seen in all patients included fever, chills, 
headache, cold-like symptoms, and fatigue, among many others, and are 
displayed in Table 5. None of the toxicities required any dose reduction or 
management as they went away with time (Gollamudi et al., 2010). Overall, no 
DLT was reached indicating that intravenous infusion of reovirus was safe and 
fairly well-tolerated, even at the maximum dose of 3x1010 TCID50. This 
investigation highlights an important point on the safety of using live, replication-
competent reovirus and its potential for future therapies. 
 Of the 18 patients enrolled in the study, 16 were evaluable for tumor 
responses using RECIST criteria. One patient with breast cancer experienced 
PR with 34% reduction in tumor burden and 12 other patients experienced SD as 
their best response. Interestingly, no relationship was found between a higher 
dose level and higher incidence of clinical benefit. Overall, this investigation 
demonstrated the effectiveness and safety of cancer therapy with Reolysin®, 
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even though all the patients experienced some toxicity believed to be related to 
regular infection with reovirus (Gollamudi et al. 2010). 
Table 5. Adverse Effects Experienced by Patients Across Doses Following 
Intravenous Reovirus Treatment. The various adverse events experienced by 
patients in this study are shown. Abbreviations: Grade 1 (G1) and Grade 2 (G2). 
(Gollamudi et al. 2010) 
Dose Level 1 2 3 4 5 6 
TCID50 
1 × 108 3 × 108 1 × 109 3 × 10
9 1 × 1010 3 × 1010 
G1 G2 G1 G2 G1 G2 G1 G2 G1 G2 G1 G2 
Fever 2                 1 3   
Chills 1   1   1       1       
Myalgia     1       2   3   2   
Headache 2       1       1   1   
Sore throat/Nasal 
fullness 2           1   2       
Fatigue     2 1     1   2   1   
Dehydration 1                       
Nausea 1   1           1   2   
Vomiting     1       1   1       
Diarrhea 1   3       1           
Constipation     1           1       
Bloating                 1       
Anorexia     1       1   1   1   
Dysgeusia                     1   
Skin rash                 1       
  
In another phase I study of intravenous administration of reovirus in 
patients with advanced cancers, Vidal and colleagues used Reolysin® to examine 
the safety and efficacy of intravenous administration. Patients were divided into 
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eight cohorts, with the first cohort given a single dose every four weeks at 1x108 
TCID50 and the last cohort given doses for five consecutive days every four 
weeks at 3x108 TCID50 (Vidal et al., 2008).   
Thirty-three patients with various malignant diagnoses were enrolled in the 
study and had a median age of 59.5 with ages ranging from 32-80. Cancers 
included head and neck, prostate, colorectal, pancreatic, and other types.  
Similar to the previous study by Gollamudi et al., treatment was well 
tolerated and no DLT was reached. A dose of 3x1010 TCID50 for five consecutive 
days every four weeks was defined as the MTD as it was the highest dose 
available for administration (Vidal et al., 2008). The most common adverse 
effects seen were fever, chills, fatigue, nausea, and vomiting. Overall the protocol 
was shown to be safe and recommended for future investigations. Moreover, 
although no objective responses using RECIST criteria were made, there were 
indications of antitumor activity including in 8 patients with radiologic evidence of 
stable disease.  
In their phase II trial examining the antitumor effect of Reolysin® in 
patients with metastatic melanoma, Galanis and colleagues also used 
intravenous administration. Reolysin® was given at a dose of 3x1010 TCID50 for 
five consecutive days every four weeks (Galanis et al., 2012) 
 Twenty-three patients were enrolled in the study and twenty-one 
were eligible for treatment. Patients had a median age of 65 years and with ages 
		
 27	
ranging from 22-80 years. Many of them had received prior therapies before 
enrolling in the study. 
Overall, the treatment was well-tolerated with a few severe (grade 3-4) 
treatment-related toxicities including fatigue, lymphopenia, and hyponatremia. 
The most common toxicities were mild (grade 2 or less) and included nausea, 
fever, and anemia (Galanis et al., 2012). 
Tumor responses were evaluated using RECIST criteria and no PR or CR 
were observed. However one patient did show extensive tumor necrosis in two of 
their metastatic lesions that had to be surgically removed. In this investigation 15 
patients had biopsies done to evaluate for reovirus infection. Of the 15, 13 
contained metastatic tumors, and in 2 out of the 13, productive reovirus 
replication was detected (Figure 3). Interestingly the median progression-free 
survival rate of patients enrolled in this study was 45 days, but the two patients 
with reovirus replication in their metastatic tumors survived for 80 and 87 days 
(Galanis et al., 2012).  
Although this study does not support the use of intravenous administration 
of reovirus as a monotherapy for malignant melanoma, it does highlight its ability 
to infect and replicate in melanoma metastases. One factor that may have 
resulted in this low treatment efficacy is the presence of NARA in patients. 
Researchers saw a multiple fold increase in neutralizing antibodies against 
reovirus in all patients treated in the study so a decrease in efficacy due to NARA 
may have been possible. In general, intravenous administration of reovirus may 
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prove to be advantageous in combatting metastatic cancer in future 
investigations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Expression of Reoviral Proteins in Post-treatment Biopsies. (A) 
Hemotoxylin and eosin stain. (B) Reovirus stain (red). (C) Tubulin stain (green). 
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(D) Cells that show coexpression of reoviral proteins and tubuin are fluorescent 
yellow. (E) Higher magnification of an area of double positive cells indicating 
active reovirus infection. (F) Coexpression of reovirus (red) with p38 (green) are 
fluorescent yellow. (Galanis et al. 2012) 
 
REOVIRUS IN COMBINED THERAPIES – METASTATIC CANCERS 
 As the previous studies have shown, Reolysin® alone can infect tumors 
and produce some beneficial effects in cancer patients with both primary and 
metastatic tumors. While on its own it may not possess the desired strength 
needed to promote its use as a cancer monotherapy, researchers recognized its 
potential and began investigating its use in combined therapies. 
In a phase I study combining intravenous administration of reovirus with 
docetaxel, Comins and colleagues investigated the safety and efficacy of using 
this combination therapy in patients with advanced cancer. Docetaxel is an 
antineoplastic drug that disrupts the normal process of microtubule assembly and 
disassembly. Reovirus had previously been shown to associate with 
microtubules and thus docetaxel may play a role in making viral replication more 
efficient (Comins et al. 2010).  The investigation used a dose-escalation design 
with three cohorts. Each cohort was given 75mg/m2 docetaxel through 
intravenous infusion for one hour every three weeks and intravenous infusion of 
T3D replication-competent reovirus (Reolysin®) for five consecutive days every 
three weeks at doses of either 3x109 TCID50, 1x1010 TCID50, or 3x1010 TCID50.  
Twenty-five patients were enrolled in the study with a median age of 60 
years and ages ranging from 32-77 years and twenty-three patients completed at 
		
 30	
least 1 cycle of treatment. The study included patients with advanced or 
metastatic solid tumors, including melanoma, prostate, pancreatic, stomach, and 
breast, for which no curative standard therapy was available (Comins et al. 
2010). 
Overall the treatment was well-tolerated with common side effects 
including diarrhea, fatigue, fever, chills, and neutropenia. Moreover there were 
six grade 4 adverse effects, with four of them occurring in the highest dose 
cohort. However, these four were attributed to docetaxel therapy alone (Comins 
et al., 2010). One DLT was reached due to grade 4 neutropenia and while MTD 
was not reached the study authors recommended a dose of 3x1010 TCID50 with 
75 mg/m2 of docetaxel for future studies (Comins et al., 2010).  
Sixteen patients were eligible for response assessment that was carried 
out according to RECIST criteria. One CR was reported in the liver of a patient 
with metastatic breast carcinoma. Three patients had evidence of PR and ten 
other patients had evidence of SD. However it is impossible to determine 
whether responses were due to either agent alone or through combination. Three 
patients had post-treatment biopsies taken and reovirus proteins were detected 
in all of these biopsies, indicating that reovirus was transported to sites of 
metastases (Comins et al., 2010). In general, this investigation highlights the 
potential benefit of administering combined treatments of reovirus with current 
antineoplastic drugs.  
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In another trial examining the combined therapy of Reolysin® with 
carboplatin and paclitaxel chemotherapy, Karapanagiotu and colleagues used a 
dose-escalation design to determine the safety and DLT/MTD of the combined 
treatment in patients with advanced or metastatic malignancies. Patients were 
given 175 mg/m2 of paclitaxel and area under curve (AUC) 5 of carboplatin 
through intravenous infusion for one day every three weeks. Three dose cohorts 
of either 3x109, 1x1010, or 3x1010 TCID50 of reovirus were used to administer to 
patients intravenously for one hour for five consecutive days every three weeks 
(Karapanagiotou et al., 2012) 
Thirty-four patients were enrolled in the study, while thirty-one received 
treatment. Patients had a median age of 60 years with ages ranging from 27-79 
years and varying cancer diagnoses such as squamous cell cancer of head and 
neck, melanoma, and sarcoma.  
Treatment was well-tolerated by patients with the most common toxicities 
including blood cytopenias, nausea, vomiting, fatigue, diarrhea, fever, chills, and 
muscle pain (Karapanagiotou et al., 2012). Some grade 3/4 toxicities were also 
observed, including neutropenia, asymptomatic lymphopenia, and anemia. 
However, no relationship between reovirus dose level and incidence or grade of 
symptoms was found. No MTD was reached for reovirus treatment and many of 
the adverse events seen were not uncommon in chemotherapy alone. 
To assess tumor responses to treatment RECIST criteria was used. Of the 
31 patients treated, 26 had received at least two cycles of treatment and were 
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evaluable for tumor response in their primary tumors. One patient had CR, 6 
patients had PR, 9 patients had SD, and 8 patients had PD. The other 2 patients 
were not evaluable by RECIST, but had major clinical responses in radiation 
pretreated lesions and one of them even had a nearly complete disappearance of 
disfiguring lesions (Karapanagiotou et al., 2012). Overall, this combined 
treatment was shown to be safe and effective in treating patients with advanced 
malignancies. However, this study was limited in determining efficacy of 
treatment for metastatic cancers by not examining tumor response in 
metastases.  
 Lolkema and colleagues investigated the safety and efficacy of combining 
intravenous reovirus treatment with gemcitabine to attenuate the neutralizing 
antibody response against reovirus. Previous studies in mice with human colon 
cancer xenografts showed the synergy produced by in vivo treatment with 
Reolysin® and gemcitabine with pathologic complete remission in 4/5 mice (Lane 
et al. 2007). Gemcitabine was administered through 30-minute intravenous 
infusion at a dose of 1000 mg/m2 on days 1 and 8 of a three-week cycle. Initially, 
Reolysin® was planned to be administered for five consecutive days every three 
weeks, but the first two patients treated experienced DLT and protocol was 
changed to administer Reolysin® at day 1 only of each three-week cycle. Four 
escalating dose levels were used with the lowest being 1x109 TCID50 and the 
highest being 3x1010 TCID50 (Lolkema et al., 2011). 
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 Sixteen patients were enrolled in the study with ages ranging from 36-72 
years. Patients were diagnosed with varying solid malignancies, including 
colorectal, breast, squamous cell carcinoma, and fibrosarcoma.  
 The most common adverse effects reported include pyrexia, nausea, 
diarrhea, vomiting, chills, and increased ALT. These were generally mild or 
moderate. As mentioned previously, two patients experienced DLT at a dose of 
3x1010 TCID50 of reovirus for 5 consecutive days every three weeks with 1000 
mg/m2 of gemcitabine on days 1 and 8. These DLTs were due to a rise in liver 
enzymes, ALT and AST, which is known to be a common side effect of 
gemcitabine (Lolkema et al. 2011). Although an MTD was not determined, study 
authors recommend a dose of 1x1010 TCID50 of reovirus on day 1 and 1000 
mg/m2 of gemcitabine on days 1 and 8 of a three-week cycle for future trials.  
 Ten patients were evaluable for tumor response and had completed at 
least 2 cycles of treatment. One patient with metastatic nasopharyngeal 
carcinoma had PR according to RECIST and another with breast cancer showed 
decreased tumor size. Six other patients showed SD. Gemcitabine was used to 
attenuate the NARA response, which researchers hoped would allow reovirus to 
spread more easily to other tissues. Overall, the study showed a modest efficacy 
for the combined treatment, but warrants further study for ideal dose levels and 
to elucidate mechanisms for the efficacy. 
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REOVIRUS IN COMBINED THERAPIES – RAS METASTATIC CANCERS 
 The previous studies examined patients with various tumor types, not 
excluding patients with cancers unrelated to activating mutations in Ras. As 
mentioned before some studies concluded that Ras activation status did not 
affect infectivity of reovirus, while others state that Ras activation plays a role in 
reovirus infectivity and replication. One investigation discovered that the majority 
of cancers of the exocrine pancreas were related to activating mutations in K-ras 
genes (Almoguera et al., 1988). In their phase 2 trial of Reolysin® combined with 
carboplatin and paclitaxel, Noonan and colleagues investigated the efficacy of 
this combined therapy in patients with metastatic pancreatic adenocarcinomas 
(2016). All patients received intravenous infusion of 175 mg/m2 of paclitaxel over 
three hours followed by AUC5 carboplatin over thirty minutes on day 1 of a three-
week cycle. Patients in Arm A also received intravenous infusion of Reolysin® at 
3x1010 TCID50 for five consecutive days every three weeks while patients in Arm 
B did not (Noonan et al., 2016).  
 Seventy-three patients with a median age of 64 years and ages ranging 
from 39-84 were treated in the study. Thirty-six patients were randomized to Arm 
A and the other thirty-seven to Arm B. Patients had varying metastases to the 
liver, lung, peritoneum, and other sites with about half the patients having 
metastases in three or more sites (Noonan et al., 2016).  
 The treatment was well-tolerated by the patients with no significant 
differences in adverse effects between each arm. However there were two 
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occurrences of lupus nephritis attributed to treatment with Reolysin® and both 
were resolved after discontinuing virus treatment.  
 Out of the 73 patients treated, only 5 had progression free survival (PFS) 
and the remaining 68 had disease progression and/or death. The study found no 
significant difference in PFS between treatment arms with Arm A having a 
median PFS of 4.9 versus 5.2 months for Arm B. Furthermore, no significant 
difference in overall survival (OS) was found between treatment arms with Arm A 
having a median OS of 7.3 months versus 8.8 for Arm B. Looking at tumor 
response, seven patients in each arm displayed PR. Moreover SD was seen in 
53% of patients in Arm A and 49% of patients in Arm B. Overall, combination 
therapy of Reolysin® with carboplatin and paclitaxel did not improve PFS in 
patients with pancreatic adenocarcinoma when compared to treatment with 
carboplatin and paclitaxel alone (Noonan et al., 2016). Interestingly, this study 
provides some evidence that K-ras status does not influence tumor response or 
survival outcomes in patients treated with reovirus combined with 
chemotherapeutics. 
 In another investigation evaluating Reolysin® combined with paclitaxel and 
carboplatin, Villalona-Calero and colleagues treated KRAS-activated tumors in 
patients with metastatic or recurrent non-small cell lung cancer (2016). Patients 
were given intravenous administration of AUC 6 mg/ml/min of carboplatin and 
200 mg/m2 of paclitaxel on day one of the three-week cycle. Reolysin® was also 
administered intravenously at a dose of 3x1010 TCID50 for five consecutive days 
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every three weeks (Villalona-Calero et al. 2016). Compared to previous studies 
with this combined therapy, this investigation started by using slightly higher 
doses for carboplatin and paclitaxel. After the first two patients treated with these 
starting doses experienced unacceptable toxicities, doses for carboplatin and 
paclitaxel were reduced to AUC5 and 175 mg/m2 respectively for all patients for 
the remainder of the study, matching the doses of previous studies (Villalona-
Calero et al., 2016).  
 Thirty-seven patients with median age of 65 years and ages ranging from 
47-82 years were treated in the study. Patients had varying molecular alterations 
including 20 with KRAS mutations, 10 with epidermal growth factor receptor 
(EGFR) amplifications, 3 with EGFR mutations, and 4 with BRAF-V600E 
mutations.  
 The most frequent moderate to severe adverse effects observed included 
fatigue, neutropenia, diarrhea, nausea, and vomiting. Overall, the treatment was 
well tolerated and had a good safety profile. Chemotherapy was further reduced 
for 6 patients due to adverse events and Reolysin® dose was reduced for only 1 
patient.  
 Out of the thirty-seven patients treated, only 35 were evaluable for a 
response. According to RECIST criteria 11 out of 35 showed PR. When 
comparing tumor responses according to molecular alteration, 5 out of 18 with 
KRAS mutation showed PR, 3 out of 10 with EGFR amplification mutation 
showed PR, and 2 out of 4 with BRAF mutation showed PR. These results 
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indicated that the type of KRAS-activating mutation in the tumor did not affect 
tumor response. Moreover because the study lacked a control group with non-
KRAS-activated tumors the study could not confirm or reject the use of Ras as a 
predictor for Reolysin® activity (Villalona-Calero et al., 2016).  
 
INTRAVENOUS REOVIRUS TREATMENT – BLOOD CANCERS 
While the safety and efficacy of reovirus treatment in solid tumor cancers has 
been shown, its potential use as a therapy for blood cancers such as myeloma 
and leukemia is still being investigated. Previous studies have shown that 
reovirus can induce ER-stress mediated apoptosis in myeloma cells, thus 
demonstrating a benefit in attempting to treat some blood cancers with 
intravenous reovirus.  
In their phase I clinical trial, Sborov and colleagues investigated the safety 
and efficacy of utilizing intravenous administration of Reolysin® in patients with 
relapsed multiple myeloma (2014). Two dose cohorts at either 3x109 TCID50 or 
3x1010 TCID50 were used in which all patients were given intravenous infusion of 
Reolysin® for five consecutive days in four-week cycles. 
 A total of twelve patients with a median age of 61 years and ages ranging 
from 48-77 years were enrolled in the study. All patients had received prior 
treatment with lenalidomide and bortezomib (Sborov et al., 2014). 
 Overall the treatment was well-tolerated and no DLT was reached. Three 
patients experienced grade 3 neutropenia and two experienced grade 3 
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leukopenia. Grade 2 toxicities included leukopenia, anemia, neutropenia, 
thrombocytopenia, and myalgias (Sborov et al., 2014). 
 Response assessment was conducted according to International Myeloma 
Working Group (IMWG) Uniform response criterion (Durie et al., 2006). The best 
response observed was stable disease. In cycle 1, 5 patients displayed 
decreased myeloma proteins, 3 had slight increases, and the other 4 showed 
signs of progressive disease. Seven patients had adequate tissue samples for 
pre- and post-treatment bone marrow biopsies and in all seven reovirus RNA 
was found. Moreover reovirus protein was also found in five of these biopsies 
indicating evidence of reovirus cell entry and replication (Sborov et al., 2014). In 
general, this investigation demonstrated that treatment of multiple myeloma with 
a 3x1010 TCID50 dose of Reolysin® was safe, with some moderate adverse 
effects, but only showed a modest efficacy. While reovirus was shown to infect 
cells, replication and apoptosis were limited.  
 
IMMUNE SYSTEM EFFECTS OF REOVIRUS 
While infecting cancer cells and inducing apoptosis is one function of 
oncolytic reovirus that investigators hoped could be used as future therapy, 
recent studies have shown that reovirus has another function that can promote 
antitumor activity. During their phase II trial, Noonan and colleagues discovered 
that treatment with Reolysin® significantly increased multiple cytokines such as 
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IL-10, RANTES, SDF-1, and VEGFA and concluded that reovirus exposure has 
some proinflammatory effects (Noonan et al., 2016).  
 In another investigation by Errington and colleagues, T3D reovirus was 
found to induce dendritic cell (DC) maturation and promote innate immunity 
against tumors (Errington et al., 2008).  Human myeloid DCs were used in the 
study due to their presence in the tumor environment. DCs treated with reovirus 
matured and secreted inflammatory cytokines such as TNF-𝛼, IL-6, and IL-12. 
These reovirus-activated DCs were then co-cultured with autologous natural killer 
(NK) or T cells and induced IFN-𝛾 production in both NK and T cells indicating 
their activation (Errington et al., 2008). This research study provides further 
evidence for the immune modulating function of reovirus.   
 Reovirus not only helps activate innate immunity, but may also play a role 
in activating adaptive immunity as well. Similar to Errington’s study, Prestwich 
and colleagues cultured DCs with T3D reovirus-infected melanoma cells and 
found that they induced DCs to mature. These induced DCs were then co-
cultured with peripheral blood lymphocytes which then displayed lymphocyte 
expansion, IFN-𝛾 production, anti-melanoma cytotoxicity, and cross-priming of 
CD8+ T cells against melanoma tumor associated antigen, MART-1 (Prestwich et 
al., 2008). Interestingly, when researchers cultured dendritic cells with melanoma 
cells alone they found that no induction of DC maturation or cytokine production 
was found.  
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In another study by Prestwich, researchers identified that viral lysis of 
tumor cells was not necessary in order to generate antitumor immunity. 
Researchers used melanoma cell lines B16tk (found to be susceptible to reovirus 
infection and killing) and B16ova (found to be resistant to reovirus infection and 
killing). T3D reovirus replication failed to occur when administered to B16ova 
cells in vitro or in vivo while reovirus-mediated oncolysis failed to occur in vitro 
only. Moreover, it was found that reovirus did not reduce tumor burden when 
administered to immunodeficient mice bearing B16ova cells. However, reovirus 
did succeed in reducing tumor burden in immunocompetent mice, supporting the 
idea that it may  prime host immune cells in the absence of viral oncolysis 
(Prestwich et al., 2009).  
In their investigation of the potential of reovirus as therapy for patients with 
chronic lymphocytic leukemia (CLL), Parrish and colleagues found that 
replication-competent reovirus was directly cytotoxic against CLL cells (2015). 
Moreover, along with direct cytotoxicity, reovirus stimulated NK cells through an 
IFN𝛼-dependent mechanism, as well as enhanced antibody-dependent cellular 
cytotoxicity against CLL (Parrish et al., 2015). Similarly, Hall and colleagues 
found that T3D reovirus could also infect, replicate in, and kill acute myeloid 
leukemia (AML) cells of myeloblastic and monocytic origin. Moreover, reovirus 
was able to induce secretion of IFN𝛼 and chemokine RANTES from infected 
AML cells leading to activation of dendritic cells and the development of anti-
leukemic responses (Hall et al. 2012). 
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CONCLUSION 
 Reovirus is a ubiquitous virus that most people are first exposed to as 
children when it may cause asymptomatic or benign infections resulting in cold-
like symptoms or diarrhea. The development of protective antibodies likely 
prevents symptoms upon repeated exposures, which likely occur throughout the 
lifetime of the host. Reovirus has also been shown to be oncolytic, preferentially 
infected and killing certain types of tumor cells. Several studies have investigated 
whether reovirus might cause more serious diseases in humans and tested this 
theory by examining neutralizing antibody titers against reovirus in patients with 
idiopathic liver disease or primary biliary cirrhosis (Minuk et al. 1987)(Minuk, 
Paul, and Lee 1985). Although in both studies patients that were believed to have 
developed their diseases due to reovirus infections had slightly higher antibody 
titers when compared with healthy individuals, the difference was not significant 
to support reovirus as a causative agent. 
Overall, after an examination of the published findings from clinical trials 
involving T3D reovirus (Reolysin®) treatment in solid tumors, metastatic cancers, 
and one blood cancer, the evidence suggests that reovirus administered as 
either intratumoral injection or intravenously is safe and generally well-tolerated. 
The studies evaluated in this investigation provide evidence to support the 
hypothesis that utilization of T3D reovirus as a treatment for cancers is effective 
and provides benefits that offset the adverse events that might occur from its 
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use. The maximum dose used in any study involving intratumoral injection was 
six injections over the course of three weeks at a dose of 1x1010 TCID50 and was 
recommended for future treatments (Harrington et al. 2010). Similarly the 
maximum recommended dose for intravenous infusion of reovirus was 3x1010 
TCID50 for 5 consecutive days every three or four weeks.  
Interestingly, Reolysin® has been found to have sufficient potential in 
treating a wide variety of cancers. Several studies examined in this investigation 
have provided evidence of reovirus infection and replication in tumors such as 
melanoma, myeloma, leukemia, head and neck cancer, breast cancer, sarcoma, 
and many others. Research is also continuously being done to examine the 
potential of Reolysin® treatment of cancers that have yet to be examined. For 
example, T3D reovirus was found to induce apoptosis in prostate cancer cells 
indicating its potential use in prostate cancers (Thirukkumaran et al. 2010). 
Another study showed cytopathic effects of T3D reovirus in peritoneal 
metastases of human gastric cancer (Kawaguchi et al. 2010). The potential of 
using reovirus to treat various cancers is also enhanced by the fact that it can be 
administered in multiple ways.  
Both intratumoral injection and intravenous infusion are delivery methods 
shown to allow reovirus to reach tumors and exert its effects. However, both 
display advantages and disadvantages. Although NARA levels were shown to 
increase in all patients given intratumoral injections of reovirus, the intratumoral 
approach is believed to have an advantage over intravenous infusion in that it is 
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less likely to be affected by a NARA response because it places reovirus in direct 
contact with tumor cells (Harrington et al. 2010). The intratumoral approach has 
also shown greater efficacy in patients when compared with the intravenous 
approach with one complete response reported in a study by Morris and 
colleagues (Morris et al. 2013). These are two clear benefits of intratumoral 
administration of Reolysin that warrant its use in patients. However, intravenous 
administration allows the virus to travel through the circulatory system and 
encounter tumor cells throughout the body. This approach has been 
advantageous for blood cancers in which solid tumors are rarely available for 
treatment and in metastatic cancers in which lesions are found in multiple 
locations in the patient.  
In general, both forms of administration provide benefits based on the type 
of cancer present, whether a primary solid tumor cancer or blood/metastatic 
cancer, and the main deciding factor for what treatment approach to use should 
be determined by the type of cancer a patient has. Primary solid tumor cancers 
should be treated with intratumoral injection due to the greater efficacy of 
treatment seen because it allows for expedited delivery to tumor, delivery of 
higher viral load, and avoidance of immune clearance (Kolb et al. 2015) On the 
other hand, blood/metastatic cancers should be treated intravenously due to the 
greater spread of the virus in the system to be able to encounter cancer cells that 
are also found in various sites in these patients.  
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Some major concern of intravenous infusion of reovirus are its attenuation 
by neutralizing antibodies in the host and ability to deliver an effective viral load 
to tumors (Comins et al. 2010). The future of Reolysin® as a treatment for cancer 
will likely be as a part of a combination therapy with immune modulators or 
chemotherapeutic agents. One investigation attempted to decrease the NARA 
response by combining reovirus treatment with cyclophosphamide, but their 
results demonstrated that addition of cyclophosphamide did not significantly 
influence host antiviral responses (Roulstone et al. 2015). However another 
study combining reovirus with cyclophosphamide yielded positive results in that 
the addition of cyclophosphamide was found to modulate neutralizing antibodies 
(Qiao et al. 2008).  When comparing the efficacy of intravenous Reolysin® alone 
versus in combination therapies, the clinical trials examined in this study provide 
some evidence for the benefit combined therapy produces. On its own, reovirus 
only showed a modest efficacy when administered intravenously, however 
greater efficacies were seen in the combination therapies.  
Interestingly, one investigation sought a new method of intravenously 
administering reovirus by loading it into blood mononuclear cells to avoid a 
NARA response (Adair et al. 2013). One extra benefit noted in the study is that 
this method also helped to stimulate NK cells to kill tumor targets, by inducing an 
innate immune-mediated response (Adair et al. 2013). Evidence has been seen 
for the dual ability of reovirus to directly induce tumor oncolysis and recruit innate 
and adaptive immune cells to target cancer cells. Unfortunately, one limitation of 
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the current clinical trials is that they have not fully examined this second ability of 
reovirus to activate host immune cells in cancer patients. Future studies and 
clinical trials should be conducted to examine the synergistic potential of 
combining reovirus with immune checkpoint inhibitors.   
One research study by Carlson, Bultz, and Morris examined the quality of 
life and distress in patients enrolled in a phase I trial of Reolysin® (2005). The 
study interviewed sixteen patients with incurable metastatic cancer and found 
that all patients were hopeful and excited to begin the trial with 2/3 of them 
hoping for disease regression and 1/3 hoping for a cure (Carlson, Bultz, and 
Morris, 2005). Research studies and clinical trials provide hope for patients 
afflicted with untreatable diseases and are the key to discovering new 
treatments. At this time, extensive research has been done in investigating the 
effects of Reolysin® both alone and in combination with other therapies for 
patients with solid tumor cancers and metastases. However, future studies are 
needed in order to better evaluate the efficacy of these treatments and elucidate 
mechanisms that may increase their potential. Moreover, not many trials have 
been done investigating the efficacy of reovirus treatment in patients with blood 
cancers even though research studies have shown its potential. Thus future 
studies investigating the efficacy of Reolysin® alone and in combination with other 
therapies in patients with blood cancers should be done. 
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